Articles tagged with Cancer Medication
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
A study found that only 43% of accelerated approval drugs demonstrated a clinical benefit in confirmatory trials after five years. The study analyzed 129 cancer drugs approved between 2013-2023 and found that 63% were converted to regular approvals, but 22% were withdrawn due to lack of efficacy.
Most cancer drugs granted accelerated approval show no benefit in overall survival or quality of life within five years. Patients should be informed about the limited effectiveness of these drugs.
A phase 2 study by Dana-Farber Cancer Institute investigators found notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer, including six out of 16 patients experiencing tumor reduction. The combination of mirvetuximab soravtansine and pembrolizumab met its primary endpoint and showed promise for ...
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers have found that combining DNMT and EZH2 inhibitors activates viral mimicry in cancer cells, making them more susceptible to attack by the immune system. The combination therapy has shown potential in treating colorectal cancers and other solid tumors, with an upcoming Phase I clinical trial planned.
Researchers have identified a protein, NPEPPS, that enables cisplatin-resistant cancer cells to become responsive to treatment. This discovery could increase patient eligibility and make platinum-based therapies more effective.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
Patients from socially vulnerable areas show increased treatment adherence when treated at 340B-participating hospitals compared to non-participating hospitals. The study found no difference in use between 340B and non-340B hospitals but noted improved adherence among patients from disadvantaged areas.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
A Canadian Medical Association Journal study finds that financial distress affects up to 33% of cancer patients in Canada, causing direct, indirect, and emotional costs. The authors suggest supporting home care, improved benefit plans, and pharmacare to alleviate the financial burden on patients and their families.
Research reveals oestrogen's protective role in preventing fatty liver disease by targeting the TEAD1 protein. The discovery could lead to a new treatment for fatty liver and liver cancer, as well as earlier detection methods.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
Researchers analyzed access to new treatments for early-stage lung cancer in Europe, highlighting existing disparities in healthcare systems and reimbursement structures. The study calls for a collective European approach to reduce inequalities in access to care.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
Researchers at University at Buffalo propose a new approach to developing cancer drugs by determining the optimal placement of molecular linkers earlier in the process, reducing trial and error and increasing potency, according to a study published in Communications Chemistry.
A study by Universitat Autonoma de Barcelona demonstrates that vorinostat, an anti-cancer drug, mitigates brain injuries and restores brain tissue after a stroke. Researchers found that the treatment not only protects the brain but also surrounding vessels, reducing inflammation and improving neurological deficits.
A study found that over half of cancer drugs approved through expedited pathways recover research and development costs within three years, despite lacking proof of added benefit. The researchers emphasize the need for better alignment between regulatory and reimbursement processes to promote effective drug development.
A new study found that many newly approved EU oncology drugs lack proof of added benefit, with over half recovering R&D costs within three years. This challenges the industry's claim that high drug prices are necessary to offset R&D expenses.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
New research led by Johns Hopkins Medicine reveals that age-related changes in fibroblast cells enable pancreatic cancer tumor growth. The study found that older patients have poorer prognoses due to altered proteins released by fibroblasts, which promote cancer cell growth and spread.
A new study from the University of Ottawa proposes using vanoxerine, a drug initially developed for cocaine addiction, to potentially treat advanced colon cancer. Vanoxerine has been found to suppress cancer stem cell activity in colon cancer patients' tissues and tumours implanted in laboratory animals. The drug works by interfering w...
A new study published in The Lancet Oncology demonstrates that the drug enobosarm has anti-tumour effects in oestrogen receptor positive breast cancer patients, providing a novel approach to treatment. The study showed that enobosarm was well tolerated with no significant impact on quality of life.
Researchers identified mechanisms that cause ponatinib to harm the heart and found a promising treatment that could reverse this process. The treatment protects heart cells without diminishing the tumor-fighting efficacy of the drug.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
A new study shows that inhibiting TACC3 can restore the effectiveness of T-DM1 in HER2-positive breast cancer cells, which have developed resistance. This is achieved by inducing immunogenic cell death and enhancing the response to the drug.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
A new proteogenomics study provides insights into how drug resistance develops in acute myeloid leukemia, offering a potential path forward for treatment. Researchers identified specific proteins and molecular locations that play a key role in determining protein activity, which could help doctors switch to alternative medications.
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.
AI-based personalized medicine is developing rapidly, enabling tailored therapies for individual patients. However, existing regulatory frameworks create significant challenges for approving these novel treatments.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
Researchers identified genetic variants that predict response to treatment for preterm birth, a condition affecting one in 10 infants. High levels of mutations in certain genes are associated with lower response rates, suggesting a precision framework for future drug development.
Researchers developed a new reagent called t-BuSF to improve the synthesis of sulfur-containing compounds used in medicines. The use of t-BuSF decreased reaction times and improved stability, enabling efficient production of these compounds.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers at Cleveland Clinic have developed a peptide therapeutic that blocks aggressive cancer cells from multiplying rapidly. The treatment disrupts the molecular processes behind cancer growth and induces tumor cell death, making it a promising new strategy for treating triple-negative breast cancer.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
Researchers have developed a novel method to produce a selective anticancer precursor substance. The synthesis involves the reaction of metal-active oxygen species with nitrile, utilizing cost-effective metals at lower temperatures. This breakthrough opens up new possibilities in developing innovative drugs against cancer.
A study by the University of Sydney and University of Warwick found large gaps in evidence regarding opioid medicines for cancer pain. Non-opioid medicines, including aspirin, may be as effective as opioids for background cancer pain.
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.
A study found that over 13% of cancer drug trials in China used suboptimal control arms, which may lead to biased results and patient harm. The researchers highlight the need for refining trial design to generate optimal clinical evidence.
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
Researchers leverage AI to analyze healthcare data and identify new targets for effective therapies and accelerate drug development in aging research. AI can tailor cancer treatment more precisely to individual patients' unique aging profiles, optimizing treatment outcomes and minimizing risks.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A phase III trial found that tucatinib plus trastuzumab emtansine extended progression-free survival in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, particularly those with brain metastases. The combination reduced the risk of disease progression or death by 24.1% and improved outcomes for pati...